Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Gastrointestinal 3Plasma cell 2Lymphoid 2Sarcoma 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
tucatinib × Gastrointestinal × 90 days × Clear all
NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡